Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2014 |
| Start Date: | April 2013 |
| Contact: | Kristen Rushton |
| Email: | krushton@myriad.com |
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
This registry is intended to evaluate the impact of genomic test results towards selecting a
first-line therapy option for newly diagnosed localized prostate cancer patients.
first-line therapy option for newly diagnosed localized prostate cancer patients.
Inclusion Criteria:
- Newly diagnosed (≤6 months), untreated patients with histologically proven
adenocarcinoma of the prostate that have the following characteristics.
- Clinically localized (no evidence on clinical or imaging studies of advanced
disease).
- No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or
antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
- Sufficient amount of tissue remains from biopsy to perform genomic testing.
Exclusion Criteria:
- Patients with a known history of hypogonadism
We found this trial at
1
site
Click here to add this to my saved trials
